FBIO Fortress Biotech, Inc.: institutional ownership and insider trading
58 funds reported holding $23.4M of Fortress Biotech, Inc. in their latest 13F filings; in Q2 2026 funds net bought $1.67M, with 13 new positions and 11 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $68.5M and net income of $142M.
FBIO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $18.7M, net income −$468K, EPS -0.08
- Quarter ended Mar 31, 2026: revenue $16.0M, net income $110M, EPS 2.82
- Quarter ended Dec 31, 2025: revenue $16.1M, net income $26.2M, EPS -0.15
- Quarter ended Sep 30, 2025: revenue $17.6M, net income $5.85M, EPS 0.11
Famous investors holding FBIO
- Two Sigma (Two Sigma Investments): $654K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $415K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $264K, 0.0% of the portfolio
Largest institutional holders of FBIO
- VANGUARD GROUP INC — $4.03M
- VANGUARD CAPITAL MANAGEMENT LLC — $3.17M
- Opaleye Management Inc. — $2.72M
- MACKENZIE FINANCIAL CORP — $1.70M
- GSA CAPITAL PARTNERS LLP — $1.40M
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $1.37M
- GEODE CAPITAL MANAGEMENT, LLC — $920K
- BlackRock, Inc. (BLK) — $688K
- TWO SIGMA INVESTMENTS, LP — $654K
- SHIKIAR ASSET MANAGEMENT INC — $654K
5%+ owners
- Lindsay A. Rosenwald, M.D.: 20.7% (Schedule 13D/A, filed Mar 20, 2026)
- Highbridge Capital Management, LLC: 7.8% (Schedule 13G/A, filed May 15, 2026)
- Millennium Management LLC: 5.3% (Schedule 13G, filed Sep 1, 2026)